| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Lan Zhang | |
| Frank Stüber | |||
| Ulrike M Stamer | |||
| P2860 | cites work | Influence of psychological factors on risk of temporomandibular disorders. | Q51731198 |
| Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. | Q51774127 | ||
| Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. | Q51809173 | ||
| Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. | Q51955912 | ||
| CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. | Q52271601 | ||
| The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. | Q54566435 | ||
| Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. | Q54593894 | ||
| No Influence of ABCB1 Haplotypes on Methadone Dosage Requirement | Q57550236 | ||
| ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment | Q57550258 | ||
| Environmental and genetic factors associated with morphine response in the postoperative period | Q57611840 | ||
| Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms | Q58193493 | ||
| Progress in genetic studies of pain and analgesia | Q24289028 | ||
| Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans | Q28239493 | ||
| Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response | Q28252209 | ||
| Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother | Q28258937 | ||
| Codeine intoxication associated with ultrarapid CYP2D6 metabolism | Q28300589 | ||
| Replicating genotype-phenotype associations | Q29614919 | ||
| COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor | Q33964426 | ||
| Effect of the CYP2C9*3 allele on lornoxicam metabolism | Q46719025 | ||
| Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. | Q46731224 | ||
| Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol | Q46801811 | ||
| The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. | Q46861856 | ||
| Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament | Q47443562 | ||
| Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans | Q48326066 | ||
| Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. | Q48463805 | ||
| Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. | Q48664314 | ||
| Tramadol: a review of its use in perioperative pain | Q33993699 | ||
| CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. | Q34302849 | ||
| Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan | Q34346859 | ||
| Codeine phosphate in paediatric medicine | Q34382377 | ||
| Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research | Q34391905 | ||
| Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? | Q34445132 | ||
| Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites | Q34522442 | ||
| Methadone use in cancer patients with pain: a review | Q34525701 | ||
| Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects | Q34655750 | ||
| Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 | ||
| Clinically important drug interactions with anticoagulants. An update | Q34734558 | ||
| Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone | Q34979384 | ||
| Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans | Q34983212 | ||
| New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme | Q34994964 | ||
| Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies | Q35003605 | ||
| Pharmacogenetics in drug regulation: promise, potential and pitfalls | Q35038052 | ||
| The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. | Q35827277 | ||
| Clinical consequences of cytochrome P450 2C9 polymorphisms | Q36002222 | ||
| Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene | Q36016764 | ||
| Pharmacogenomics and individualized drug therapy | Q36366823 | ||
| Persistent postsurgical pain: risk factors and prevention | Q36477806 | ||
| Pharmacogenetics of opioids | Q36752672 | ||
| ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence | Q37008505 | ||
| Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain | Q37102220 | ||
| Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women | Q37158552 | ||
| Evidence for a biopsychosocial influence on shoulder pain: pain catastrophizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings. | Q37159861 | ||
| Variable response to opioid treatment: any genetic predictors within sight? | Q37187101 | ||
| Pharmacogenetics of analgesics: toward the individualization of prescription | Q37205954 | ||
| Genome-wide association study of acute post-surgical pain in humans | Q37228216 | ||
| Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain | Q37259162 | ||
| Establishing causality of CNS depression in breastfed infants following maternal codeine use. | Q37322259 | ||
| Transition from acute to chronic postsurgical pain: risk factors and protective factors | Q37464199 | ||
| Genetic modulation of the pharmacological treatment of pain | Q37554918 | ||
| Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment | Q37580433 | ||
| Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. | Q37611786 | ||
| Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. | Q39329852 | ||
| Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer | Q39334234 | ||
| Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy | Q39348026 | ||
| Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability | Q39636584 | ||
| Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication | Q40057474 | ||
| Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans | Q41672099 | ||
| The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers | Q41854197 | ||
| Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. | Q42554140 | ||
| Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. | Q43244977 | ||
| Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery | Q43269189 | ||
| Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery | Q43270791 | ||
| Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia | Q43283102 | ||
| Codeine, ultrarapid-metabolism genotype, and postoperative death | Q43289451 | ||
| Codeine and morphine pathway | Q43480688 | ||
| In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics | Q43598159 | ||
| Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. | Q44085582 | ||
| Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT). | Q44138252 | ||
| One size does not fit all: genetic variability of mu-opioid receptor and postoperative morphine consumption | Q44331473 | ||
| Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty | Q44331545 | ||
| A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain | Q44332189 | ||
| ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals | Q44333294 | ||
| A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia | Q44339910 | ||
| Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study | Q44339918 | ||
| Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females*. | Q44340770 | ||
| A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain | Q44341121 | ||
| High post surgical opioid requirements in Crohn's disease are not due to a general change in pain sensitivity | Q44341315 | ||
| Novel linkage disequilibrium of single nucleotide polymorphisms in the transcriptional regulatory region of micro-opioid receptor gene in Japanese population | Q44342153 | ||
| Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers | Q44343033 | ||
| Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study | Q44343433 | ||
| Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells | Q44344646 | ||
| The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease | Q44347117 | ||
| CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers | Q44432237 | ||
| Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites | Q44534415 | ||
| Impact of CYP2D6 genotype on postoperative tramadol analgesia | Q44589963 | ||
| The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon | Q44884452 | ||
| CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians | Q44960515 | ||
| Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms | Q45004302 | ||
| Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy | Q45182394 | ||
| Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? | Q46036338 | ||
| The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism | Q46090850 | ||
| Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects | Q46091447 | ||
| Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. | Q46257861 | ||
| Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers | Q46434971 | ||
| The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients | Q46520044 | ||
| Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers | Q46544571 | ||
| Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants | Q46551884 | ||
| P433 | issue | 6 | |
| P921 | main subject | pain management | Q621261 |
| P304 | page(s) | 843-864 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Personalized therapy in pain management: where do we stand? | |
| P478 | volume | 11 |
| Q34165511 | Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. |
| Q24621760 | Applications of CYP450 testing in the clinical setting |
| Q88528844 | Clinical application of pharmacogenetics in pain management |
| Q38100710 | Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications |
| Q33351201 | Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol |
| Q38811685 | How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity |
| Q35092973 | Osteoarthritis subpopulations and implications for clinical trial design |
| Q40349015 | Paracetamol for perioperative analgesia. Old substance - new insights |
| Q44372482 | Personalized medicine--one size fits one: tailoring pain therapy to individuals' needs |
| Q38071975 | Personalized treatment of pain |
| Q42737748 | PharmGKB summary: tramadol pathway |
| Q26859221 | Pharmacogenetics and anaesthesia: the value of genetic profiling |
| Q34070615 | Pharmacogenetics and pharmacogenomics in rheumatology. |
| Q38050316 | Pharmacogenetics of nonsteroidal anti-inflammatory drugs |
| Q38025139 | Pharmacogenetics of pain and analgesia |
| Q34316700 | Pharmacogenomic considerations in opioid analgesia. |
| Q40924040 | Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment |
| Q26765266 | The pharmacogenomics of pain management: prospects for personalized medicine |
| Q27015822 | Tramadol Extended-Release for the Management of Pain due to Osteoarthritis |
| Q83516240 | [Physicians do not treat averages--but therapy responders!] |
Search more.